Abstract
Objective This study aimed to assess the prevalence of CM, treatment practice, and the associated factor’s post-introduction of Tenofovir Lamivudine and Dolutegravir (TLD) regimen among PLHIV in Tanzania.
Methods This was an analytical cross-sectional study, and the data was collected retrospectively in three public regional referral hospitals (RRHs) in Dar es Salaam, Tanzania. A total of 405 files of the PLHIV admitted in the medical wards on the TLD regimen from January 2019 to December 2022 were reviewed. The collected information includes patient demographic characteristics, Cryptococcal status, CD4 level at the time of CM diagnosis, status of using ART, CM treatment approach, and outcome. Data was analyzed using SPSS software version 23.
Results Out of 405, the majority 267(65.9%) were female, 224(55.3%) were aged between 36 - 55 years, and 293(72.3%) married. ART defaulters were found to be 37(9.1%). The prevalence of CM was found to be 48(11.9%), out of which 42(87.5%) received fluconazole alone. ART defaulter and marital status significantly (p-value < 0.05) were associated with those who tested CM positive.
Conclusion The study found the prevalence of CM among PLHIV to be significantly high and the majority were treated with fluconazole alone. ART defaulters and marital status were significantly associated with one being CM positive. Responsible authorities and stakeholders should enforce guideline adherence and PLHIV should be encouraged on medication adherence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was ethical cleared by the Muhimbili University of Health and Allied Sciences- Research and Ethics Committee with Ref No. DA. 282/298/01L/602. In the protocol it was stated clearly that the study will retrieve patient information from their medical records so consent form will be administered. In addition, we received permission to collect data from the respective hospital administration before commencement of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
VI. List of abbreviation
- 5-FC
- 5-fluorocytosine(Flucytosine)
- ART
- Antiretroviral Therapy
- CTC
- Care and Treatment Centre
- CD4
- Clusters of Differentiation 4
- CM
- Cryptococcal meningitis
- PLHIV
- People Living With Human Immunodeficiency Virus
- HIV
- Human Immunodeficiency Virus
- HCPs
- Health Care Providers
- IPT
- Isoniazid Prophylaxis Therapy
- LIC
- Lower Income Countries
- MUHAS
- Muhimbili University of Health and Allied Sciences
- RRH
- Regional Referral Hospitals
- SPSS
- Statistical Package for Social Science
- TLD
- Tenofovir Lamivudine Dolutegravir
